Alembic Pharmaceuticals today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg.
 
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Wellbutrin Tablets, 75 mg and 100 mg, of GlaxoSmithKline LLC. Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg is indicated for the treatment of major depressive disorder.

Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg, have an estimated market size of USD 37 million for twelve months ending December 2017 according to IMS.

Alembic now has a total of 72 ANDA approvals (64 final approvals and 8 tentative approvals) from USFDA.

Shares of the company gained Rs 28.95, or 6.66%, to trade at Rs 463.80. The total volume of shares traded was 11,932 at the BSE (10.28 a.m., Monday).